Abstract
Schizophrenia is considered to develop as a consequence of genetic and environmental factors impacting on brain neural systems and circuits during vulnerable neurodevelopmental periods, thereby resulting in symptoms in early adulthood. Understanding of the impact of schizophrenia risk factors on brain biology and behaviour can help in identifying biologically relevant pathways that are attractive for informing clinical studies and biomarker development. In this chapter, we emphasize the importance of adopting a reciprocal forward and reverse translation approach that is iteratively updated when additional new information is gained, either preclinically or clinically, for offering the greatest opportunity for discovering panels of biomarkers for the diagnosis, prognosis and treatment of schizophrenia. Importantly, biomarkers for identifying those at risk may inform early intervention strategies prior to the development of schizophrenia.
Given the emerging nature of this approach in the field, this review will highlight recent research of preclinical biomarkers in schizophrenia that show the most promise for informing clinical needs with an emphasis on relevant imaging, electrophysiological, cognitive behavioural and biochemical modalities. The implementation of this reciprocal translational approach is exemplified firstly by the production and characterization of preclinical models based on the glutamate hypofunction hypothesis, genetic and environmental risk factors for schizophrenia (reverse translation), and then the recent clinical recognition of the thalamic reticular thalamus (TRN) as an important locus of brain dysfunction in schizophrenia as informed by preclinical findings (forward translation).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Alcantara S, Soriano E, Ferrer I (1996) Thalamic and basal forebrain afferents modulate the development of parvalbumin and calbindin D28k immunoreactivity in the barrel cortex of the rat. Eur J Neurosci 8(7):1522–1534. https://doi.org/10.1111/j.1460-9568.1996.tb01615.x
Allen P et al (2015) Functional outcome in people at high risk for psychosis predicted by thalamic glutamate levels and prefronto-striatal activation. Schizophr Bull 41(2):429–439. https://doi.org/10.1093/schbul/sbu115
Anticevic A et al (2014) Characterizing thalamo-cortical disturbances in schizophrenia and bipolar illness. Cereb Cortex 24(12):3116–3130. https://doi.org/10.1093/cercor/bht165
Ayhan Y, McFarland R, Pletnikov MV (2016) Animal models of gene-environment interaction in schizophrenia: a dimensional perspective. Prog Neurobiol 136:1–27. https://doi.org/10.1016/j.pneurobio.2015.10.002
Barch DM, Smith E (2008) The cognitive neuroscience of working memory: relevance to CNTRICS and schizophrenia. Biol Psychiatry 64:11–17. https://doi.org/10.1016/j.biopsych.2008.03.003
Barch DM et al (2009) CNTRICS final task selection: working memory. Schizophr Bull 35(1):136–152. https://doi.org/10.1093/schbul/sbn153
Belujon P, Patton MH, Grace AA (2013) Disruption of prefrontal cortical-hippocampal balance in a developmental model of schizophrenia: reversal by sulpiride. Int J Neuropsychopharmacol 16(3):507–512. https://doi.org/10.1017/S146114571200106X
Benetti S et al (2009) Functional integration between the posterior hippocampus and prefrontal cortex is impaired in both first episode schizophrenia and the at risk mental state. Brain J Neurol 132(Pt 9):2426–2436. https://doi.org/10.1093/brain/awp098
Brandon NJ et al (2009) Understanding the role of DISC1 in psychiatric disease and during normal development. J Neurosci 29(41):12768–12775. https://doi.org/10.1523/JNEUROSCI.3355-09.2009
Breier A et al (1997) Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry 154(6):805–811. https://doi.org/10.1176/ajp.154.6.805
Bussey TJ et al (2012) New translational assays for preclinical modelling of cognition in schizophrenia: the touchscreen testing method for mice and rats. Neuropharmacology 62(3):1191–1203. https://doi.org/10.1016/j.neuropharm.2011.04.011
Bussey TJ, Barch DM, Baxter MG (2013) Testing long-term memory in animal models of schizophrenia: suggestions from CNTRICS. Neurosci Biobehav Rev 37(9):2141–2148. https://doi.org/10.1016/j.neubiorev.2013.06.005
Buzsáki G, Watson BO (2012) Brain rhythms and neural syntax: implications for efficient coding of cognitive content and neuropsychiatric disease. Dialogues Clin Neurosci 14(4):345–367. https://doi.org/10.1097/ALN.0b013e318212ba87
Callicott JH et al (2013) DISC1 and SLC12A2 interaction affects human hippocampal function and connectivity. J Clin Investig 123(7):2961–2964. https://doi.org/10.1172/JCI67510
Camchong J et al (2011) Altered functional and anatomical connectivity in schizophrenia. Schizophr Bull 37(3):640–650. https://doi.org/10.1093/schbul/sbp131
Carter CS et al (2009) CNTRICS final task selection: social cognitive and affective neuroscience-based measures. Schizophr Bull 35:153–162. https://doi.org/10.1093/schbul/sbn157
Chan MK et al (2015) Development of a blood-based molecular biomarker test for identification of schizophrenia before disease onset. Transl Psychiatry 5(7). https://doi.org/10.1038/tp.2015.91
Clapcote SJ et al (2007) Behavioral phenotypes of Disc1 missense mutations in mice. Neuron 54(3):387–402. https://doi.org/10.1016/j.neuron.2007.04.015
Clementz BA et al (2016) Identification of distinct psychosis biotypes using brain-based biomarkers. Am J Psychiatry 173(4):373–384. https://doi.org/10.1176/appi.ajp.2015.14091200
Cochran SM et al (2002) Acute and delayed effects of phencyclidine upon mRNA levels of markers of glutamatergic and GABAergic neurotransmitter function in the rat brain. Synapse 46(3):206–214. https://doi.org/10.1002/syn.10126
Cochran SM et al (2003) Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs. Neuropsychopharmacology 28(2):265–275. https://doi.org/10.1038/sj.npp.1300031
Cole DM et al (2013) Differential and distributed effects of dopamine neuromodulations on resting-state network connectivity. NeuroImage 78:59–67. https://doi.org/10.1016/j.neuroimage.2013.04.034
Cosgrove J, Newell TG (1991) Recovery of neuropsychological functions during reduction in use of phencyclidine. J Clin Psychol 47(1):159–169. https://doi.org/10.1002/1097-4679(199101)47:1<159::AID-JCLP2270470125>3.0.CO;2-O
Dauvermann MR et al (2013) The application of nonlinear dynamic causal modelling for fMRI in subjects at high genetic risk of schizophrenia. NeuroImage 73:16–29. https://doi.org/10.1016/j.neuroimage.2013.01.063
Dauvermann MR, Lee G, Dawson N (2017) Glutamatergic regulation of cognition and functional brain connectivity: insights from pharmacological, genetic and translational schizophrenia research. Br J Pharmacol 174:3136–3160. https://doi.org/10.1111/bph.13919
Dawson N et al (2012) Modafinil reverses phencyclidine-induced deficits in cognitive flexibility, cerebral metabolism, and functional brain connectivity. Schizophr Bull 38(3):457–474. https://doi.org/10.1093/schbul/sbq090
Dawson N, Morris BJ, Pratt JA (2013) Subanaesthetic ketamine treatment alters prefrontal cortex connectivity with thalamus and ascending subcortical systems. Schizophr Bull 39(2):366–377. https://doi.org/10.1093/schbul/sbr144
Dawson N et al (2014a) Subanesthetic ketamine treatment promotes abnormal interactions between neural subsystems and alters the properties of functional brain networks. Neuropsychopharmacology 39(7):1786–1798. https://doi.org/10.1038/npp.2014.26
Dawson N et al (2014b) Sustained NMDA receptor hypofunction induces compromised neural systems integration and schizophrenia-like alterations in functional brain networks. Cereb Cortex 24(2):452–464. https://doi.org/10.1093/cercor/bhs322
Dawson N, Morris BJ, Pratt JA (2015a) Functional brain connectivity phenotypes for schizophrenia drug discovery. J Psychopharmacol 29(2):169–177. https://doi.org/10.1177/0269881114563635
Dawson N et al (2015b) Altered functional brain network connectivity and glutamate system function in transgenic mice expressing truncated disrupted-in-schizophrenia 1. Transl Psychiatry 5(5):e569. Available at http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4471291&tool=pmcentrez&rendertype=abstract
de Wit S et al (2017) Individual prediction of long-term outcome in adolescents at ultra-high risk for psychosis: applying machine learning techniques to brain imaging data. Hum Brain Mapp 38(2):704–714. https://doi.org/10.1002/hbm.23410
Demontis D et al (2011) Association of GRIN1 and GRIN2A-D with schizophrenia and genetic interaction with maternal herpes simplex virus-2 infection affecting disease risk. Am J Med Genet B Neuropsychiatr Genet 156(8):913–922. https://doi.org/10.1002/ajmg.b.31234
Deserno L et al (2012) Reduced prefrontal-parietal effective connectivity and working memory deficits in schizophrenia. J Neurosci 32(1):12–20. https://doi.org/10.1523/JNEUROSCI.3405-11.2012
Dickerson DD, Wolff AR, Bilkey DK (2010) Abnormal long-range neural synchrony in a maternal immune activation animal model of schizophrenia. J Neurosci 30(37):12424–12431. https://doi.org/10.1523/JNEUROSCI.3046-10.2010
Dickerson F et al (2016) Inflammatory markers in recent onset psychosis and chronic schizophrenia. Schizophr Bull 42(1):134–141. https://doi.org/10.1093/schbul/sbv108
Dudchenko PA et al (2013) Animal models of working memory: a review of tasks that might be used in screening drug treatments for the memory impairments found in schizophrenia. Neurosci Biobehav Rev 37:2111–2124. https://doi.org/10.1016/j.neubiorev.2012.03.003
Duncan GE et al (1999) Comparison of brain metabolic activity patterns induced by ketamine, MK-801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine. Brain Res 843(1–2):171–183. https://doi.org/10.1016/S0006-8993(99)01776-X
Duncan EJ et al (2003) Effect of treatment status on prepulse inhibition of acoustic startle in schizophrenia. Psychopharmacology 167(1):63–71. https://doi.org/10.1007/s00213-002-1372-z
Dunlop J, Brandon NJ (2015) Schizophrenia drug discovery and development in an evolving era: are new drug targets fulfilling expectations? J Psychopharmacol 29(2):230–238. https://doi.org/10.1177/0269881114565806
Dzirasa K et al (2009) Hyperdopaminergia and NMDA receptor hypofunction disrupt neural phase signaling. J Neurosci 29(25):8215–8224. https://doi.org/10.1523/JNEUROSCI.1773-09.2009
Egerton A et al (2008) Subchronic and chronic PCP treatment produces temporally distinct deficits in attentional set shifting and prepulse inhibition in rats. Psychopharmacology 198(1):37–49. https://doi.org/10.1007/s00213-008-1071-5
Esslinger C et al (2009) Neural mechanisms of a genome-wide supported psychosis variant. Science 324(5927):605. https://doi.org/10.1126/science.1167768
Fernandes BS et al (2016) C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications. Mol Psychiatry 21(4):554–564. https://doi.org/10.1038/mp.2015.87
Ferrarelli F, Tononi G (2017) Reduced sleep spindle activity point to a TRN-MD thalamus-PFC circuit dysfunction in schizophrenia. Schizophr Res 180:36–43. https://doi.org/10.1016/j.schres.2016.05.023
Fervaha G et al (2014) Impact of primary negative symptoms on functional outcomes in schizophrenia. Eur Psychiatry 29(7):449–455. https://doi.org/10.1016/j.eurpsy.2014.01.007
Forbes NF et al (2009) Working memory in schizophrenia: a meta-analysis. Psychol Med 39(6):889–905. https://doi.org/10.1017/S0033291708004558
Fornito A et al (2011) General and specific functional connectivity disturbances in first-episode schizophrenia during cognitive control performance. Biol Psychiatry 70(1):64–72. https://doi.org/10.1016/j.biopsych.2011.02.019
Gandal MJ et al (2012) Gamma synchrony: towards a translational biomarker for the treatment-resistant symptoms of schizophrenia. Neuropharmacology 62:1504–1518. https://doi.org/10.1016/j.neuropharm.2011.02.007
Gilmour G et al (2012) NMDA receptors, cognition and schizophrenia – testing the validity of the NMDA receptor hypofunction hypothesis. Neuropharmacology 62(3):1401–1412. https://doi.org/10.1016/j.neuropharm.2011.03.015
Gilmour G et al (2013) Measuring the construct of executive control in schizophrenia: defining and validating translational animal paradigms for discovery research. Neurosci Biobehav Rev 37:2125–2140. https://doi.org/10.1016/j.neubiorev.2012.04.006
Godsil BP et al (2013) The hippocampal-prefrontal pathway: the weak link in psychiatric disorders? Eur Neuropsychopharmacol 23:1165–1181. https://doi.org/10.1016/j.euroneuro.2012.10.018
Goetghebeur P, Dias R (2009) Comparison of haloperidol, risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rat-a back translational study. Psychopharmacology 202(1–3):287–293. https://doi.org/10.1007/s00213-008-1132-9
Gonzalez-Burgos G, Cho RY, Lewis DA (2015) Alterations in cortical network oscillations and parvalbumin neurons in schizophrenia. Biol Psychiatry 77(12):1031–1040. https://doi.org/10.1016/j.biopsych.2015.03.010
Green MF et al (2000) Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”? Schizophr Bull 26(1):119–136. https://doi.org/10.1093/oxfordjournals.schbul.a033430
Green MF, Kern RS, Heaton RK (2004) Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res 72(1):41–51. https://doi.org/10.1016/j.schres.2004.09.009
Hall J, Trent S, Thomas KL, O’Donovan MC, Owen MJ (2015) Genetic risk for schizophrenia: convergence on synaptic pathways involved in plasticity. Biol Psychiatry 77:52–58
Harrison PJ (2015) Recent genetic findings in schizophrenia and their therapeutic relevance. J Psychopharmacol 29(2):85–96. https://doi.org/10.1177/0269881114553647
Herron JW et al (2018) Neuroimmune biomarkers in mental illness. Curr Top Behav Neurosci. https://doi.org/10.1007/7854_2018_45
Hill K et al (2004) Hypofrontality in schizophrenia: a meta-analysis of functional imaging studies. Acta Psychiatr Scand 110(4):243–256. https://doi.org/10.1111/j.1600-0447.2004.00376.x
Holcomb HH et al (2000) Brain activation patterns in schizophrenic and comparison volunteers during a matched-performance auditory recognition task. Am J Psychiatry 157(10):1634–1645. https://doi.org/10.1176/appi.ajp.157.10.1634
Homayoun H, Moghaddam B (2007) NMDA receptor Hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 27(43):11496–11500. https://doi.org/10.1523/JNEUROSCI.2213-07.2007
Hu W et al (2015) The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies. Ann N Y Acad Sci 1338(1):38–57. https://doi.org/10.1111/nyas.12547
Hugdahl K et al (2015) Glutamate as a mediating transmitter for auditory hallucinations in schizophrenia: a 1H MRS study. Schizophr Res 161(2–3):252–260. https://doi.org/10.1016/j.schres.2014.11.015
Hunter SA, Lawrie SM (2018) Imaging and genetic biomarkers predicting transition to psychosis. Curr Top Behav Neurosci. https://doi.org/10.1007/7854_2018_46
Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia [see comments]. Am J Psychiatry 148:1301–1308. https://doi.org/10.1176/ajp.148.10.1301
Javitt DC et al (2018) Utility of imaging-based biomarkers for glutamate-targeted drug development in psychotic disorders: a randomized clinical trial. JAMA Psychiatry 75(1):11–19. https://doi.org/10.1001/jamapsychiatry.2017.3572
Jentsch JD, Roth RH (1999) The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201–225. https://doi.org/10.1016/S0893-133X(98)00060-8
Jones CA, Watson DJG, Fone KCF (2011) Animal models of schizophrenia. Br J Pharmacol 164(4):1162–1194. https://doi.org/10.1111/j.1476-5381.2011.01386.x
Kambeitz J et al (2014) Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: systematic review and meta-analysis of imaging studies. Br J Psychiatry 204:420–429. https://doi.org/10.1192/bjp.bp.113.132308
Kapur S, Mizrahi R, Li M (2005) From dopamine to salience to psychosis-linking biology, pharmacology and phenomenology of psychosis. Schizophr Res 79:59–68. https://doi.org/10.1016/j.schres.2005.01.003
Kauppi K et al (2014) Polygenic risk for schizophrenia associated with working memory-related prefrontal brain activation in patients with schizophrenia and healthy controls. Schizophr Bull 41(3):15–18. https://doi.org/10.1093/schbul/sbu152
Korotkova T et al (2010) NMDA receptor ablation on parvalbumin-positive interneurons impairs hippocampal synchrony, spatial representations, and working memory. Neuron 68(3):557–569. https://doi.org/10.1016/j.neuron.2010.09.017
Krystal JH et al (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51(3):199–214. https://doi.org/10.1001/archpsyc.1994.03950030035004
Lahti AC et al (1995) Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13(1):9–19. https://doi.org/10.1016/0893-133X(94)00131-I
Large CH (2007) Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs? J Psychopharmacol 21(3):283–301. https://doi.org/10.1177/0269881107077712
Leng A et al (2003) Effect of the 5-HT6 receptor antagonists Ro04-6790 and Ro65-7199 on latent inhibition and prepulse inhibition in the rat: comparison to clozapine. Pharmacol Biochem Behav 75(2):281–288. https://doi.org/10.1016/S0091-3057(03)00082-0
Lewis DA et al (1999) Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia. Biol Psychiatry 46:616–626. https://doi.org/10.1016/S0006-3223(99)00061-X
Lisman JE, Jensen O (2013) The theta-gamma neural code. Neuron 77:1002–1016. https://doi.org/10.1016/j.neuron.2013.03.007
Liu Y et al (2008) Disrupted small-world networks in schizophrenia. Brain 131(4):945–961. https://doi.org/10.1093/brain/awn018
Luck SJ, Gold JM (2008) The construct of attention in schizophrenia. Biol Psychiatry 64(1):34–39. https://doi.org/10.1016/j.biopsych.2008.02.014
Lustig C et al (2013a) CNTRICS final animal model task selection: control of attention. Neurosci Biobehav Rev 37:2099–2110. https://doi.org/10.1016/j.neubiorev.2012.05.009
Lustig C et al (2013b) CNTRICS final animal model task selection: control of attention. Neurosci Biobehav Rev 37(9):2099–2110. https://doi.org/10.1016/j.neubiorev.2012.05.009
Lydon-Staley DM, Bassett DS (2018) Network neuroscience: a framework for developing biomarkers in psychiatry. Curr Top Behav Neurosci. https://doi.org/10.1007/7854_2018_41
Lynall ME et al (2010) Functional connectivity and brain networks in schizophrenia. J Neurosci 30(28):9477–9487. https://doi.org/10.1523/JNEUROSCI.0333-10.2010
Mackeprang T, Kristiansen KT, Glenthoj BY (2002) Effects of antipsychotics on prepulse inhibition of the startle response in drug-naive schizophrenic patients. Biol Psychiatry 52(9):863–873. https://doi.org/10.1016/s0006-3223(02)01409-9
MacQueen DA et al (2018) Cognitive phenotypes for biomarker identification in mental illness: forward and reverse translation. Curr Top Behav Neurosci. https://doi.org/10.1007/7854_2018_50
Manoach DS (2003) Prefrontal cortex dysfunction during working memory performance in schizophrenia: reconciling discrepant findings. Schizophr Res 60:285–298. https://doi.org/10.1016/S0920-9964(02)00294-3
Martinez ZA et al (2000) “Early” and “late” effects of sustained haloperidol on apomorphine- and phencyclidine-induced sensorimotor gating deficits. Neuropsychopharmacology 23(5):517–527. https://doi.org/10.1016/S0893-133X(00)00147-0
McIntosh AR, Lobaugh NJ (2004) Partial least squares analysis of neuroimaging data: applications and advances. NeuroImage 23(Suppl 1):S250–263. https://doi.org/10.1016/j.neuroimage.2004.07.020
Meador-Woodruff JH et al (2003) Molecular abnormalities of the glutamate synapse in the thalamus in schizophrenia. Ann N Y Acad Sci 1003:75–93. https://doi.org/10.1196/annals.1300.005
Merritt K et al (2016) Nature of glutamate alterations in schizophrenia a meta-analysis of proton magnetic resonance spectroscopy studies. JAMA Psychiatry 73(7):665–674. https://doi.org/10.1001/jamapsychiatry.2016.0442
Meyer-Lindenberg AS et al (2005) Regionally specific disturbance of dorsolateral prefrontal-hippocampal functional connectivity in schizophrenia. Arch Gen Psychiatry 62(4):379–386. https://doi.org/10.1001/archpsyc.62.4.379
Micheloyannis S et al (2006) Small-world networks and disturbed functional connectivity in schizophrenia. Schizophr Res 87(1–3):60–66. https://doi.org/10.1016/j.schres.2006.06.028
Millan MJ, Bales KL (2013) Towards improved animal models for evaluating social cognition and its disruption in schizophrenia: the CNTRICS initiative. Neurosci Biobehav Rev 37(9):2166–2180. https://doi.org/10.1016/j.neubiorev.2013.09.012
Millan MJ et al (2014) Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur Neuropsychopharmacol 24(5):645–692. https://doi.org/10.1016/j.euroneuro.2014.03.008
Miller BJ et al (2011) Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 70(7):663–671. https://doi.org/10.1016/j.biopsych.2011.04.013
Miller BJ, Culpepper N, Rapaport MH (2014) C-reactive protein levels in schizophrenia: a review and meta-analysis. Clin Schizophr Relat Psychoses 7(4):223–230. https://doi.org/10.3371/CSRP.MICU.020813
Mitchell EJ et al (2017) Effects of phencyclidine in social groups of adolescent rats monitored in the home cage. J Psychopharmacol 31(suppl A109):E32
Miyamoto S et al (2001) Blunted brain metabolic response to ketamine in mice lacking D(1A) dopamine receptors. Brain Res 894(2):167–180
Moghaddam B et al (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17(8):2921–2927. https://doi.org/10.1016/0091-3057(93)90217-H
Molina V et al (2005) Hypofrontality in men with first-episode psychosis. Br J Psychiatry 186:203–208. https://doi.org/10.1192/bjp.186.3.203
Moore H et al (2013) Harnessing cognitive neuroscience to develop new treatments for improving cognition in schizophrenia: CNTRICS selected cognitive paradigms for animal models. Neurosci Biobehav Rev 37:2087–2091. https://doi.org/10.1016/j.neubiorev.2013.09.011
Moran P et al (2016) Gene × environment interactions in schizophrenia: evidence from genetic mouse models. Neural Plast. https://doi.org/10.1155/2016/2173748
Morris BJ, Pratt JA (2014) Novel treatment strategies for schizophrenia from improved understanding of genetic risk. Clin Genet 86(5):401–411. https://doi.org/10.1111/cge.12485
Morris BJ, Cochran SM, Pratt JA (2005) PCP: from pharmacology to modelling schizophrenia. Curr Opin Pharmacol 5(1):101–106. https://doi.org/10.1016/j.coph.2004.08.008
Nagai T, Ibi D, Yamada K (2011) Animal model for schizophrenia that reflects gene-environment interactions. Biol Pharm Bull 34(9):1364–1368. https://doi.org/10.1016/j.bbr.2009.04.010
Nieuwenstein MR, Aleman A, De Haan EHF (2001) Relationship between symptom dimensions and neurocognitive functioning in schizophrenia: a meta-analysis of WCST and CPT studies. J Psychiatr Res 35(2):119–125. https://doi.org/10.1016/S0022-3956(01)00014-0
Nuechterlein KH et al (2011) Neurocognitive predictors of work outcome in recent-onset schizophrenia. Schizophr Bull 37(suppl 2):S33–40. https://doi.org/10.1093/schbul/sbr084
Oomen CA et al (2013) The touchscreen operant platform for testing working memory and pattern separation in rats and mice. Nat Protoc 8(10):2006–2021. https://doi.org/10.1038/nprot.2013.124
Padula MC et al (2017) Multimodal investigation of triple network connectivity in patients with 22q11ds and association with executive functions. Hum Brain Mapp 38(4):2177–2189. https://doi.org/10.1002/hbm.23512
Patil ST et al (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med 13:1102–1107. Available at http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med5&NEWS=N&AN=17767166%5Cn and http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=cctr&NEWS=N&AN=CN-00627737
Perlstein WM et al (2001) Relation of prefrontal cortex dysfunction to working memory and symptoms in schizophrenia. Am J Psychiatry 158(7):1105–1113. https://doi.org/10.1176/appi.ajp.158.7.1105
Perriol M-P et al (2005) Disturbance of sensory filtering in dementia with Lewy bodies: comparison with Parkinson’s disease dementia and Alzheimer’s disease. J Neurol Neurosurg Psychiatry 76(1):106–108. https://doi.org/10.1136/jnnp.2003.035022
Pettersson-Yeo W et al (2011) Dysconnectivity in schizophrenia: where are we now? Neurosci Biobehav Rev 35:1110–1124. https://doi.org/10.1016/j.neubiorev.2010.11.004
Phillips KG et al (2012a) Decoupling of sleep-dependent cortical and hippocampal interactions in a neurodevelopmental model of schizophrenia. Neuron 76(3):526–533. https://doi.org/10.1016/j.neuron.2012.09.016
Phillips KG et al (2012b) Differential effects of NMDA antagonists on high frequency and gamma EEG oscillations in a neurodevelopmental model of schizophrenia. Neuropharmacology 62(3):1359–1370. https://doi.org/10.1016/j.neuropharm.2011.04.006
Pickard BS (2015) Schizophrenia biomarkers: translating the descriptive into the diagnostic. J Psychopharmacol 29(2):138–143. https://doi.org/10.1177/0269881114566631
Pittman-Polletta BR et al (2015) Brain rhythms connect impaired inhibition to altered cognition in schizophrenia. Biol Psychiatry 77(12):1020–1030. https://doi.org/10.1016/j.biopsych.2015.02.005
Pocklington AJ, O’Donovan M, Owen MJ (2014) The synapse in schizophrenia. Eur J Neurosci 39(7):1059–1067. https://doi.org/10.1111/ejn.12489
Potkin SG et al (2009) Working memory and DLPFC inefficiency in schizophrenia: the FBIRN study. Schizophr Bull 35(1):19–31. https://doi.org/10.1093/schbul/sbn162
Potvin S et al (2008) Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 63(8):801–808. https://doi.org/10.1016/j.biopsych.2007.09.024
Prata D, Mechelli A, Kapur S (2014) Clinically meaningful biomarkers for psychosis: a systematic and quantitative review. Neurosci Biobehav Rev 45:134–141. https://doi.org/10.1016/j.neubiorev.2014.05.010
Pratt JA, Morris BJ (2015) The thalamic reticular nucleus: a functional hub for thalamocortical network dysfunction in schizophrenia and a target for drug discovery. J Psychopharmacol 29(2):127–137. https://doi.org/10.1177/0269881114565805
Pratt JA et al (2008) Modelling prefrontal cortex deficits in schizophrenia: implications for treatment. Br J Pharmacol 153(suppl 1):S465–S470. https://doi.org/10.1038/bjp.2008.24
Pratt J et al (2012) Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap. Nat Rev Drug Discov 11(7):560–579. https://doi.org/10.1038/nrd3649
Pratt J et al (2017) Thalamo-cortical communication, glutamatergic neurotransmission and neural oscillations: a unique window into the origins of ScZ? Schizophr Res 180:4–12. https://doi.org/10.1016/j.schres.2016.05.013
Ragland JD et al (2009) CNTRICS final task selection: long-term memory. Schizophr Bull 35:197–212. https://doi.org/10.1093/schbul/sbn134. Epub 2008 Oct 16
Reddaway JT et al (2018) Genomic and imaging biomarkers in schizophrenia. Curr Top Behav Neurosci. https://doi.org/10.1007/7854_2018_52
Reddy LF, Horan WP, Green MF (2016) Motivational deficits and negative symptoms in schizophrenia: concepts and assessments. Curr Top Behav Neurosci 27:357–373. https://doi.org/10.1007/7854_2015_379
Ripke S et al (2014) Biological insights from 108 schizophrenia-associated genetic loci. Nature 511(7510):421–427. https://doi.org/10.1038/nature13595
Roiser JP et al (2013) Dysconnectivity in the frontoparietal attention network in schizophrenia. Front Psych 4:176. https://doi.org/10.3389/fpsyt.2013.00176
Rotaru DC, Lewis DA, Gonzalez-Burgos G (2012) The role of glutamatergic inputs onto parvalbumin-positive interneurons: relevance for schizophrenia. Rev Neurosci 23:97–109. https://doi.org/10.1515/revneuro-2011-0059
Salvador R et al (2017) Evaluation of machine learning algorithms and structural features for optimal MRI-based diagnostic prediction in psychosis. PLoS One 12(4). https://doi.org/10.1371/journal.pone.0175683
Scarr E et al (2015) Biomarkers for psychiatry: the journey from fantasy to fact, a report of the 2013 CINP think tank. Int J Neuropsychopharmacol 18(10):pyv042. https://doi.org/10.1093/ijnp/pyv042
Schirmer M et al (2016) Linking the human gut microbiome to inflammatory cytokine production capacity. Cell 167(4):1125–1136.e8. https://doi.org/10.1016/j.cell.2016.10.020
Schlösser R et al (2003) Altered effective connectivity during working memory performance in schizophrenia: a study with fMRI and structural equation modeling. NeuroImage 19(3):751–763. https://doi.org/10.1016/S1053-8119(03)00106-X
Schmidt A, Borgwardt S (2013) Abnormal effective connectivity in the psychosis high-risk state. NeuroImage:119–120. https://doi.org/10.1016/j.neuroimage.2013.05.035
Schmidt A et al (2014) Abnormal effective connectivity and psychopathological symptoms in the psychosis high-risk state. J Psychiatry Neurosci 39(4):239–248. https://doi.org/10.1503/jpn.130102
Scoriels L, Jones PB, Sahakian BJ (2013) Modafinil effects on cognition and emotion in schizophrenia and its neurochemical modulation in the brain. Neuropharmacology 64:168–184. https://doi.org/10.1016/j.neuropharm.2012.07.011
Sekar S et al (2013) Subchronic memantine induced concurrent functional disconnectivity and altered ultra-structural tissue integrity in the rodent brain: revealed by multimodal MRI. Psychopharmacology 227(3):479–491. https://doi.org/10.1007/s00213-013-2966-3
Senkowski D, Gallinat J (2015) Dysfunctional prefrontal gamma-band oscillations reflect working memory and other cognitive deficits in schizophrenia. Biol Psychiatry 77(12):1010–1019. https://doi.org/10.1016/j.biopsych.2015.02.034
Siegel SJ, Talpos JC, Geyer MA (2013) Animal models and measures of perceptual processing in schizophrenia. Neurosci Biobehav Rev 37(9):2092–2098. https://doi.org/10.1016/j.neubiorev.2013.06.016
Sigurdsson T et al (2010) Impaired hippocampal-prefrontal synchrony in a genetic mouse model of schizophrenia. Nature 464(7289):763–767. https://doi.org/10.1038/nature08855
Slaney C et al (2018) Translational shifts in preclinical models of depression: implications for biomarkers for improved treatments. Curr Top Behav Neurosci. https://doi.org/10.1007/7854_2018_44
Slifstein M et al (2015) Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia a positron emission tomographic functional magnetic resonance imaging study. JAMA Psychiatry 72(4):316–324. https://doi.org/10.1001/jamapsychiatry.2014.2414
Smith JW et al (2011) A comparison of the effects of ketamine and phencyclidine with other antagonists of the NMDA receptor in rodent assays of attention and working memory. Psychopharmacology 217(2):255–269. https://doi.org/10.1007/s00213-011-2277-5
Spence SA et al (2005) Modafinil modulates anterior cingulate function in chronic schizophrenia. Br J Psychiatry 187:55–61. https://doi.org/10.1192/bjp.187.1.55
Steullet P et al (2017) The thalamic reticular nucleus in schizophrenia and bipolar disorder: role of parvalbumin-expressing neuron networks and oxidative stress. Mol Psychiatry. https://doi.org/10.1038/mp.2017.230
Stirman JN, Townsend LB, Smith SL (2016) A touchscreen based global motion perception task for mice. Vis Res 127:74–83. https://doi.org/10.1016/j.visres.2016.07.006
Stone JM et al (2009) Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume. Biol Psychiatry 66(6):533–539. https://doi.org/10.1016/j.biopsych.2009.05.006
Stone JM et al (2012) Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology. Mol Psychiatry 17:664–665. https://doi.org/10.1038/mp.2011.171
Swerdlow NR, Geyer MA (1998) Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr Bull 24:285–301. https://doi.org/10.1093/oxfordjournals.schbul.a033326
Swerdlow NR et al (1995) Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington’s disease. J Neurol Neurosurg Psychiatry 58(2):192–200. https://doi.org/10.1136/jnnp.58.2.192
Tamminga CA et al (1987) PCP-induced alterations in cerebral glucose utilization in rat brain: blockade by metaphit, a PCP-receptor-acylating agent. Synapse 1(5):497–504. https://doi.org/10.1002/syn.890010514
Tomasi D, Volkow ND (2014) Mapping small-world properties through development in the human brain: disruption in schizophrenia. PLoS One 9(4):e96176. https://doi.org/10.1371/journal.pone.0096176
Turner DC et al (2004) Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology 29(7):1363–1373. https://doi.org/10.1038/sj.npp.1300457
Uhlhaas PJ, Singer W (2010) Abnormal neural oscillations and synchrony in schizophrenia. Nat Rev Neurosci 11:100–113. https://doi.org/10.1038/nrn2774
Uhlhaas PJ, Singer W (2015) Oscillations and neuronal dynamics in schizophrenia: the search for basic symptoms and translational opportunities. Biol Psychiatry 77(12):1001–1009. https://doi.org/10.1016/j.biopsych.2014.11.019
Upthegrove R, Manzanares-Teson N, Barnes NM (2014) Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis. Schizophr Res 155(1–3):101–108. https://doi.org/10.1016/j.schres.2014.03.005
Van Den Buuse M (2010) Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects. Schizophr Bull 36:246–270. https://doi.org/10.1093/schbul/sbp132
van den Heuvel MP et al (2010) Aberrant frontal and temporal complex network structure in schizophrenia: a graph theoretical analysis. J Neurosci 30(47):15915–15926. https://doi.org/10.1523/JNEUROSCI.2874-10.2010
Van Snellenberg JX et al (2016) Mechanisms of working memory impairment in schizophrenia. Biol Psychiatry 80(8):617–626. https://doi.org/10.1016/j.biopsych.2016.02.017
Weinstein JJ et al (2017) Pathway-specific dopamine abnormalities in schizophrenia. Biol Psychiatry 81:31–42. https://doi.org/10.1016/j.biopsych.2016.03.2104
Welsh RC, Chen AC, Taylor SF (2010) Low-frequency BOLD fluctuations demonstrate altered thalamocortical connectivity in schizophrenia. Schizophr Bull 36(4):713–722. https://doi.org/10.1093/schbul/sbn145
Whittington MA et al (2000) Inhibition-based rhythms: experimental and mathematical observations on network dynamics. Int J Psychophysiol 38:315–336. https://doi.org/10.1016/S0167-8760(00)00173-2
Whittington MA et al (2011) Multiple origins of the cortical gamma rhythm. Dev Neurobiol 71(1):92–106. https://doi.org/10.1002/dneu.20814
Yang M, Silverman JL, Crawley JN (2011) Automated three-chambered social approach task for mice. Curr Protoc Neurosci Chapter 8(suppl 56):Unit 8.26. https://doi.org/10.1002/0471142301.ns0826s56
Young JW, Geyer MA (2015) Developing treatments for cognitive deficits in schizophrenia: the challenge of translation. J Psychopharmacol 29:178–196. https://doi.org/10.1177/0269881114555252
Zhang Q et al (2017) Increased ratio of high sensitivity C-reactive protein to interleukin-10 as a potential peripheral biomarker of schizophrenia and aggression. Int J Psychophysiol 114:9–15. https://doi.org/10.1016/j.ijpsycho.2017.02.001
Zhou Y et al (2007) Functional dysconnectivity of the dorsolateral prefrontal cortex in first-episode schizophrenia using resting-state fMRI. Neurosci Lett 417(3):297–302. https://doi.org/10.1016/j.neulet.2007.02.081
Acknowledgements
JAP, BJM and ND jointly hold an MRC research grant (MR/N012704/1). JAP and BJM currently hold MRC grants MR/N012704/1 and IMPC-74593/1 and an academic research grant from Servier. Previous support which has contributed to the development of this work includes funding from Mitsubishi Pharma and a Pfizer Translational Medicine research programme.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Pratt, J.A., Morris, B., Dawson, N. (2018). Deconstructing Schizophrenia: Advances in Preclinical Models for Biomarker Identification. In: Pratt, J., Hall, J. (eds) Biomarkers in Psychiatry. Current Topics in Behavioral Neurosciences, vol 40. Springer, Cham. https://doi.org/10.1007/7854_2018_48
Download citation
DOI: https://doi.org/10.1007/7854_2018_48
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-99641-7
Online ISBN: 978-3-319-99642-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)